Shots:
The CHMP has adopted a positive opinion recommending EU marketing authorization for Ascendis Pharma’s once-weekly TransCon CNP (navepegritide) for achondroplasia in children aged ≥2yrs. whose epiphyses are not closed; the EC decision on the MAA is expected in Q4’26
The opinion followed review of the MAA, incl. clinical data from 3 randomized, double-blind, PBO-controlled…
